SNES News & Events

Reports Q4 revenue $421M vs. $501M last year. Cash and short-term investments of $8.6M at the end of 2025 are believed to be sufficient to provide operating runway through approximately 2Q27. "2025 marked meaningful progress, with continued field validation, revenue growth, improved margins, and a stronger balance sheet," said CEO Joel Fruendt. "We believe field validation of efficacy becomes a powerful catalyst for expanded acceptance in the market, as reflected in the strong growth of our e-commerce channel, which is now more than 50% of our annual revenue. We are leaning further into the direct-to-consumer and e-commerce opportunities, strengthening our control of the customer experience, improving performance management, and enhancing our ability to capture more value as adoption expands." "With a CEO transition plan underway, the Board remains focused on continuity, alignment, and disciplined execution as we support management in scaling the business," said Jamie Bechtel, Interim Executive Chair. "With a growing body of validation and a sharpened go-to-market approach, we are focused on executing with discipline, expanding adoption, and building long-term stockholder value."

SenesTech reported significant reductions in rodent activity following multi-month deployments of Evolve Rat Birth Control in two urban locations. "In the first monitored area, where Evolve placement began in April 2025, tracking plate data collected from August 2025 through January 2026 showed declines in both rodent presence and activity levels. The proportion of plates marked with rodent tracks declined from an average of 74% in August 2025 to 15% in January 2026, representing a 79% reduction in overall plate presence. Track density on plates with rodent presence decreased by 88% over the same period. While baseline data prior to the initial April 2025 product placement were not available, these findings indicate that within five months of monitored observation, rodent activity in the surveyed area declined in both prevalence and intensity," the company stated.

SenesTech announced that Joel Fruendt, President and CEO, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, whichever occurs first. In addition, to further support this transition, the Board has appointed Dr. Jamie Bechtel, current Chair of the Board, to the newly created role of Interim Executive Chair.